ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) closed its last session at $33.41 with the change of +4.18%. The market capitalization of the company is $3.81B with an average Volume of 2.05 million shares. The stock currently has its 52-Week High range of $43.89 and 52-week low range of $16.64. The Price to Book (P/B) ratio stands at 8.92. The stock traded total quantity of 2.25 million shares.
Currently ACADIA Pharmaceuticals Inc. (ACAD) captured an average recommendation of “ Buy ” from analysts, according to FactSet data. The stock has been suggested as “Buy” from “7″ Analysts”. “0” rated “Sell” for the company. “2” said the company as a “Hold”. Overweight rating was given by “0” and Underweight rating was given by “0”.
Analysts are expecting that the company to achieve $46.44 Price Target in next 52-weeks, average price is come up through the consensus of analysts. High potential price target is set at $60.00 however minimum price target advised by analysts is $39.00. The Median price target for the stock is measured at $45.00.
Presently, Analysts decided consensus EPS estimate of $-0.57 for present quarter and one month ago projected EPS estimate was at $-0.57. If we take a look at back 3 month ago, consensus EPS estimate was $-0.47.
A current consensus EPS estimate for next quarter is at $-0.54 and 3 month ago EPS forecast was $-0.46. Have a look at back 1 month ago, consensus EPS forecast was seen at $-0.54.
For current fiscal year, most recent EPS estimate is set at $-2.19 based on Analyst consensus and three month ago consensus EPS opinions was at $-1.78. During period one month ago, consensus EPS forecast was decided at $-2.19.
A current consensus EPS projection for next fiscal year is observed at $-1.81 and one month ago consensus EPS forecast was at $-1.81. Take a look at back three month ago, consensus EPS estimate opinions was decided at $-1.42 by analysts.
One Month ago, the stock has gained consensus mean rating of Buy based on the analysis of brokerage analyst firms polled. 7 presented the recommendations about the stock as a “Buy” signal and “Overweight” signal was reported by 0. 2 advised the “Hold” rating about this stock. 0 revealed “Sell” signal and “Underweight” rating was declared by 0.
Three Months Ago, Analysts recommended an average brokerage rating of Buy derived from brokerage firms, according to FactSet. 9 said a “Buy Rating” and 0 announced “Overweight Rating”. 1 advised “Hold Rating” regarding the stock. 0 announced “Sell Rating” and 0 disclosed “Underweight Rating”.